Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspire-Lakewood HoldingsASBP +2.42%11 Pretax Margin % is -2,012.70% as of Jun. 2026. GuruFocus rates ASBP with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 948 Biotechnology companies, Aspire-Lakewood Holdings ranks worse than 93.57% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Aspire-Lakewood Holdings Pretax Margin % Related Terms
Aspire-Lakewood Holdings Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASBP vs PDSB, KPRX, SNTI: Pretax Margin % Comparison
For the Biotechnology subindustry, Aspire-Lakewood Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspire-Lakewood Holdings Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aspire-Lakewood Holdings's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Aspire-Lakewood Holdings's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspire-Lakewood Holdings (ASBP) has a Pretax Margin % of -2,012.70% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Aspire-Lakewood Holdings and its competitors. According to the industry distribution chart, Aspire-Lakewood Holdings ranks #887 out of 948 companies in the Biotechnology industry, placing it in the top 93.6%.
Is Aspire-Lakewood Holdings' Pretax Margin % too high?
Aspire-Lakewood Holdings' current Pretax Margin % is -2,012.70%. Based on the distribution chart, Aspire-Lakewood Holdings ranks #887 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aspire-Lakewood Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Aspire-Lakewood Holdings' Pretax Margin % compare to PDSB and KPRX?
According to the Biotechnology industry distribution chart, Aspire-Lakewood Holdings ranks #887 out of 948 companies for Pretax Margin %. This places Aspire-Lakewood Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Aspire-Lakewood Holdings and its competitors. Aspire-Lakewood Holdings's current Pretax Margin % is -2,012.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspire-Lakewood Holdings stock overvalued right now?
Aspire-Lakewood Holdings (ASBP) has a current Pretax Margin % of -2,012.70%. The current Pretax Margin % is -2,012.70%. Aspire-Lakewood Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Aspire-Lakewood Holdings (ASBP), the current Pretax Margin % is -2,012.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
11GF Score
Get the complete analysis for ASBP
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASBP has been successfully added to your 
